Understanding Type 2 Inflammation: Spotlight on Asthma

Track 1 - Understanding T2 Inflammation: Spotlight on Moderate-to-Severe Asthma
Track 2 - Understanding T2 Inflammation: Best Practices in Moderate-to-Severe Asthma Management

Learn About:

1. T2 inflammation’s central role in asthma pathophysiology
2. Safety and efficacy of pharmaceuticals targeting T2 inflammation
3. Payer care management initiatives and other opportunities to improve patient access and quality of care

Expert Faculty Presenters:

Jeffrey D. Dunn, PharmD, MBA President and Chief Executive Officer Cooperative Benefits Group (CBG) Click here for biography Michael Kobernick, MD, MS, MS-PopH, CPE Senior Medical Director – Health Plan Business Blue Cross Blue Shield Of Michigan Lecturer Jefferson College of Population Health Click here for biography Anju T. Peters, MD, MSCI, FAAAAI Professor of Medicine Director of Clinical Research Division of Allergy/Immunology and Otolaryngology Northwestern University Feinberg School of Medicine Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
T2 inflammation, involving both the innate and adaptive immune systems, underpins the complex pathophysiology of chronic inflammation in asthma, as well as the presence of comorbid disease. Managed care professionals require education regarding T2 inflammation pathways in asthma and comorbidities as well as the safety and efficacy of treatments used to manage patients with moderate-to-severe asthma. This activity will explore care management strategies based on current evidence that can improve access and quality of care for patients with moderate-to-severe asthma.

Educational Objectives
After completing this activity, the participant should be better able to:

• Explain how T2 inflammation plays a central role in asthma pathophysiology and common comorbidities
• Review safety and efficacy of pharmaceuticals targeting T2 inflammation in moderate-to-severe asthma
• Cite payer care management initiatives and other opportunities to improve patient access and quality of care based on current evidence from clinical trials, real-world experience, and treatment guidelines

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
PACE designates this continuing education activity for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education.

Track 1 - 1.0 contact hour

UAN: JA4008073-9999-25-002-L01-P
Type of Activity: Application

Track 2 - 1.0 contact hour

UAN: JA4008073-9999-25-003-L01-P
Type of Activity: Application

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.